<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='../../ld1webpage.xsl'?>
<LOBBYINGDISCLOSURE1>
  <imported>N</imported>
  <pages>2</pages>
  <regType>2</regType>
  <organizationName>Sidley Austin LLP</organizationName>
  <prefix>
  </prefix>
  <firstName>
  </firstName>
  <lastName>
  </lastName>
  <address1>1501 K Street</address1>
  <address2>
  </address2>
  <city>Washington</city>
  <state>DC</state>
  <zip>20005</zip>
  <zipext>
  </zipext>
  <country>USA</country>
  <principal_city>
  </principal_city>
  <principal_state>
  </principal_state>
  <principal_zip>
  </principal_zip>
  <principal_zipext>
  </principal_zipext>
  <principal_country>
  </principal_country>
  <contactIntlPhone>
  </contactIntlPhone>
  <registrantGeneralDescription>Law firm</registrantGeneralDescription>
  <selfSelect>N</selfSelect>
  <clientName>Leadiant Biosciences, Inc.  </clientName>
  <clientAddress>9841 Washingtonian Blvd #500</clientAddress>
  <clientCity>Gaithersburg</clientCity>
  <clientState>MD</clientState>
  <clientZip>20878</clientZip>
  <clientZipExt>
  </clientZipExt>
  <clientCountry>USA</clientCountry>
  <prinClientCity>
  </prinClientCity>
  <prinClientState>
  </prinClientState>
  <prinClientZip>
  </prinClientZip>
  <prinClientZipExt>
  </prinClientZipExt>
  <prinClientCountry>
  </prinClientCountry>
  <clientGeneralDescription>Pharmaceutical manufacturer</clientGeneralDescription>
  <senateID>35230</senateID>
  <houseID>312040190</houseID>
  <lobbyists>
    <lobbyist>
      <lobbyistFirstName>Tracey</lobbyistFirstName>
      <lobbyistLastName>LaTurner</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>Professional Staff, House Appropriations Committee; Administrative Asst., House Appropriations Committee; Scheduler, Office Manager, Rep. J. Bunn </coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>Stephanie</lobbyistFirstName>
      <lobbyistLastName>Hales</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>N/A</coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>William</lobbyistFirstName>
      <lobbyistLastName>Sarraille</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>N/A</coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>Patricia</lobbyistFirstName>
      <lobbyistLastName>DeLoatche</lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>Health Policy Director, Sen. Orrin Hatch; Chief of Staff, Legislative Director, and Legislative Assistant, Rep. Mike Bilirakis</coveredPosition>
      <lobbyistNew>Y</lobbyistNew>
    </lobbyist>
    <lobbyist>
      <lobbyistFirstName>
      </lobbyistFirstName>
      <lobbyistLastName>
      </lobbyistLastName>
      <lobbyistSuffix>
      </lobbyistSuffix>
      <coveredPosition>
      </coveredPosition>
      <lobbyistNew>N</lobbyistNew>
    </lobbyist>
  </lobbyists>
  <alis>
    <ali_Code>MMM</ali_Code>
    <ali_Code>HCR</ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
    <ali_Code>
    </ali_Code>
  </alis>
  <specific_issues>Issues related to Medicare and Medicaid payment policies and value-based arrangements.</specific_issues>
  <affiliatedUrl>
  </affiliatedUrl>
  <affiliatedOrgs>
    <affiliatedOrg>
      <affiliatedOrgName>
      </affiliatedOrgName>
      <affiliatedOrgAddress>
      </affiliatedOrgAddress>
      <affiliatedOrgCity>
      </affiliatedOrgCity>
      <affiliatedOrgState>
      </affiliatedOrgState>
      <affiliatedOrgZip>
      </affiliatedOrgZip>
      <affiliatedOrgCountry>
      </affiliatedOrgCountry>
      <affiliatedPrinOrgCity>
      </affiliatedPrinOrgCity>
      <affiliatedPrinOrgState>
      </affiliatedPrinOrgState>
      <affiliatedPrinOrgCountry>
      </affiliatedPrinOrgCountry>
    </affiliatedOrg>
    <affiliatedOrg>
      <affiliatedOrgName>
      </affiliatedOrgName>
      <affiliatedOrgAddress>
      </affiliatedOrgAddress>
      <affiliatedOrgCity>
      </affiliatedOrgCity>
      <affiliatedOrgState>
      </affiliatedOrgState>
      <affiliatedOrgZip>
      </affiliatedOrgZip>
      <affiliatedOrgCountry>
      </affiliatedOrgCountry>
      <affiliatedPrinOrgCity>
      </affiliatedPrinOrgCity>
      <affiliatedPrinOrgState>
      </affiliatedPrinOrgState>
      <affiliatedPrinOrgCountry>
      </affiliatedPrinOrgCountry>
    </affiliatedOrg>
    <affiliatedOrg>
      <affiliatedOrgName>
      </affiliatedOrgName>
      <affiliatedOrgAddress>
      </affiliatedOrgAddress>
      <affiliatedOrgCity>
      </affiliatedOrgCity>
      <affiliatedOrgState>
      </affiliatedOrgState>
      <affiliatedOrgZip>
      </affiliatedOrgZip>
      <affiliatedOrgCountry>
      </affiliatedOrgCountry>
      <affiliatedPrinOrgCity>
      </affiliatedPrinOrgCity>
      <affiliatedPrinOrgState>
      </affiliatedPrinOrgState>
      <affiliatedPrinOrgCountry>
      </affiliatedPrinOrgCountry>
    </affiliatedOrg>
  </affiliatedOrgs>
  <foreignEntities>
    <foreignEntity>
      <name>Leadiant Biosciences S.p.A. </name>
      <address>via Sudafrica 20</address>
      <city>00144 Roma</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0.00</contribution>
      <ownership_Percentage>100</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Essetifin S.p.A.</name>
      <address>Via Sudafrica 20</address>
      <city>00144 Rome</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>100</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Paolo Cavazza</name>
      <address>Italy</address>
      <city>Italy</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>35.91</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Enrico Cavazza</name>
      <address>Italy</address>
      <city>Italy</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>13.47</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Francesca Cavazza</name>
      <address>Italy</address>
      <city>Italy</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>13.47</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Silvia Cavazza</name>
      <address>Italy</address>
      <city>Italy</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>13.47</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Martina Cavazza Preta</name>
      <address>Italy</address>
      <city>Italy</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>13.47</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Taufin Investments S.p.A.</name>
      <address>Via Antonio Bertoloni 1/E</address>
      <city>00197 Rome</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>6.13</ownership_Percentage>
    </foreignEntity>
    <foreignEntity>
      <name>Aptafin S.p.A.</name>
      <address>Viale William Shakespeare 47</address>
      <city>00144 Rome</city>
      <state>
      </state>
      <country>ITA</country>
      <prinCity>
      </prinCity>
      <prinState>
      </prinState>
      <prinCountry>
      </prinCountry>
      <contribution>0</contribution>
      <ownership_Percentage>4.09</ownership_Percentage>
    </foreignEntity>
  </foreignEntities>
  <reportYear>2018</reportYear>
  <reportType>RR</reportType>
  <effectiveDate>10/23/2018</effectiveDate>
  <printedName>William A. Sarraille</printedName>
  <signedDate>12/6/2018 5:21:57 PM</signedDate>
</LOBBYINGDISCLOSURE1>